Brand Planning Season is Here: Is Patient Access Strategy at the Table?

For teams developing 2027 brand plans or product launch plans, now is the time to ensure patient access strategy is built into the foundation—not added as an afterthought.

As pharmaceutical and biotech manufacturers kick off—or are already well into—their 2027 brand planning process or product launch planning, FDA approval and a strong marketing campaign are essential—but they are only part of the path to commercial success.

A successful brand strategy must also answer some critical questions:

• How will patients access therapy?
• Will the patient support program remove barriers to therapy and improve the treatment experience?
• Is the product’s 3PL/Full-Line Wholesale/Specialty Distribution model aligned with the brand’s goals to get the brand to the right dispensing entity?
• Are the current dispensing entities (Retail, Specialty Pharmacies, IDN, DTC/DTP, Infusion Center) all meeting brand expectations, or are improvements warranted?
• Does the strategy address evolving payer requirements and reimbursement challenges?

One lesson we’ve seen across brands is that a single operational issue rarely causes access challenges. More often, they stem from decisions that were made, or overlooked, during brand or launch planning. Bringing patient access into the conversation early helps align commercial strategy with operational execution, creating a stronger experience for both patients and providers.

Patient support, dispensing, distribution, and market access are no longer downstream operational considerations—they are strategic drivers that influence launch readiness, speed to therapy, patient and provider experience, and long-term brand performance. The strongest brand plans integrate these considerations early, ensuring cross-functional alignment and reducing the risk of costly changes later in the commercialization process.

When these strategies are built into brand planning from the outset, patients experience fewer delays to therapy, field teams have fewer operational issues to resolve, and commercial teams can focus on growing the brand rather than fixing access challenges.

Conversely, when access strategy is treated as an afterthought, manufacturers often find themselves redesigning patient support programs, changing distribution networks, responding to unexpected payer barriers, or making costly operational changes —creating delays for patients and slowing commercial momentum.

At Archbow Consulting, we partner with manufacturers to build actionable, patient-centered access and distribution strategies that support successful launches and sustainable brand growth. If your team is preparing for 2027 brand planning, Archbow can help translate access priorities into an action plan. Contact us to learn more.